Used in pharmaceutical research as a potent proteolysis targeting chimera (PROTAC) designed to selectively degrade target proteins involved in cancer pathways. It functions by recruiting an E3 ubiquitin ligase to tag specific disease-related proteins for degradation by the cell’s proteasome system. This compound shows high specificity and efficiency in cellular models, particularly in hematological malignancies, due to its ability to cross cell membranes and induce sustained target protein knockdown. Its structure enables enhanced stability and reduced off-target effects, making it valuable in developing targeted cancer therapies and studying protein function in cellular systems.